EE03445B1 - Tahükiniini (NK1) retseptori antagonistid - Google Patents
Tahükiniini (NK1) retseptori antagonistidInfo
- Publication number
- EE03445B1 EE03445B1 EE9600177A EE9600177A EE03445B1 EE 03445 B1 EE03445 B1 EE 03445B1 EE 9600177 A EE9600177 A EE 9600177A EE 9600177 A EE9600177 A EE 9600177A EE 03445 B1 EE03445 B1 EE 03445B1
- Authority
- EE
- Estonia
- Prior art keywords
- compounds
- tachykinin
- migraine
- pain
- receptor antagonists
- Prior art date
Links
- 102000003141 Tachykinin Human genes 0.000 title abstract 3
- 108060008037 tachykinin Proteins 0.000 title abstract 3
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000019695 Migraine disease Diseases 0.000 abstract 2
- 208000002193 Pain Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 206010027599 migraine Diseases 0.000 abstract 2
- 230000036407 pain Effects 0.000 abstract 2
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 150000001298 alcohols Chemical class 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000002111 antiemetic agent Substances 0.000 abstract 1
- 229940125683 antiemetic agent Drugs 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25482194A | 1994-06-06 | 1994-06-06 | |
| PCT/US1995/006289 WO1995033744A1 (en) | 1994-06-06 | 1995-05-18 | Tachykinin (nk1) receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EE9600177A EE9600177A (et) | 1997-06-16 |
| EE03445B1 true EE03445B1 (et) | 2001-06-15 |
Family
ID=22965712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EE9600177A EE03445B1 (et) | 1994-06-06 | 1995-05-18 | Tahükiniini (NK1) retseptori antagonistid |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5610176A (de) |
| EP (1) | EP0764163B1 (de) |
| JP (1) | JPH10501228A (de) |
| AT (1) | ATE206710T1 (de) |
| AU (1) | AU693898B2 (de) |
| CA (1) | CA2187531A1 (de) |
| DE (1) | DE69523154T2 (de) |
| DK (1) | DK0764163T3 (de) |
| EE (1) | EE03445B1 (de) |
| ES (1) | ES2165915T3 (de) |
| NZ (1) | NZ287284A (de) |
| PT (1) | PT764163E (de) |
| WO (1) | WO1995033744A1 (de) |
| ZA (1) | ZA954609B (de) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE197793T1 (de) * | 1992-08-13 | 2000-12-15 | Warner Lambert Co | Tachykinin antagonistes |
| CA2189501A1 (en) * | 1995-11-06 | 1997-05-07 | Harry R. Howard | Nk-1 receptor antagonists for the treatment of cancer |
| EP0912173A1 (de) * | 1996-06-26 | 1999-05-06 | Warner-Lambert Company | Verwendung eines tacykinin-antagonist zur herstellung eines arzneimittels zur behandlung von erbrechen |
| US5945508A (en) * | 1996-07-23 | 1999-08-31 | Witten; Mark L. | Substance P treatment for immunostimulation |
| WO1998018466A2 (en) * | 1996-10-31 | 1998-05-07 | Harbor Branch Oceanographic Institution, Inc. | Anti-neurogenic inflammatory compounds and compositions and methods of use thereof |
| US6291501B1 (en) | 1998-02-20 | 2001-09-18 | Harbor Branch Oceanographic Institution, Inc. | Compounds and methods of use for treatment of neurogenic inflammation |
| EP1140914A1 (de) | 1998-12-18 | 2001-10-10 | Warner-Lambert Company | Nicht-peptidische nk1 rezeptor antagonisten |
| EP1156054B1 (de) * | 1999-02-23 | 2004-04-14 | Ono Pharmaceutical Co., Ltd. | Medikamente, die derivate der phosphorigensäure als aktiven inhaltsstoff enthalten |
| DK1035115T3 (da) | 1999-02-24 | 2005-01-24 | Hoffmann La Roche | 4-phenylpyridinderivater og anvendelse deraf som NK-1-receptorantagonister |
| US6372440B2 (en) | 1999-03-10 | 2002-04-16 | Magnesium Diagnostics, Inc. | Method for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses |
| US6455734B1 (en) | 2000-08-09 | 2002-09-24 | Magnesium Diagnostics, Inc. | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
| US7163949B1 (en) | 1999-11-03 | 2007-01-16 | Amr Technology, Inc. | 4-phenyl substituted tetrahydroisoquinolines and use thereof |
| MXPA02004330A (es) | 1999-11-03 | 2004-07-30 | Albany Molecular Res Inc | Tetrahidroisoquinolinas aril-y heteroaril-sustituidas y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina.. |
| MXPA02008931A (es) | 2000-03-16 | 2003-02-10 | Hoffmann La Roche | Derivados de acido carboxilico como antagonistas ip. |
| AU7334901A (en) | 2000-07-11 | 2002-01-21 | Du Pont Pharm Co | Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof |
| MY130373A (en) * | 2001-10-29 | 2007-06-29 | Malesci Sas | Linear basic compounds having nk-2 antagonist activity and formulations thereof |
| WO2003101459A1 (en) * | 2002-05-29 | 2003-12-11 | The Regents Of The University Of California | Antagonizing nk1 receptors inhibits consumption of substances of abuse |
| TWI280239B (en) | 2003-07-15 | 2007-05-01 | Hoffmann La Roche | Process for preparation of pyridine derivatives |
| BRPI0513359A (pt) | 2004-07-15 | 2008-05-06 | Amr Technology Inc | tetraidroisoquinolinas substituìdas por arila e heteroarila e uso destes para bloquear a recaptação de norepinefrina, dopamina, e serotonina |
| EP1888050B1 (de) | 2005-05-17 | 2012-03-21 | Merck Sharp & Dohme Ltd. | Cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropansäure zur Behandlug von Krebs |
| UA95454C2 (uk) | 2005-07-15 | 2011-08-10 | Амр Текнолоджи, Інк. | Арил- і гетероарилзаміщені тетрагідробензазепіни і їх застосування для блокування зворотного захоплення норепінефрину, допаміну і серотоніну |
| MY143784A (en) | 2005-09-23 | 2011-07-15 | Hoffmann La Roche | Novel dosage formulation |
| KR20080048502A (ko) | 2005-09-29 | 2008-06-02 | 머크 앤드 캄파니 인코포레이티드 | 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체 |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| EP2083831B1 (de) | 2006-09-22 | 2013-12-25 | Merck Sharp & Dohme Corp. | Verfahren zur behandlung von fettsäure-synthese-hemmern |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| AR064777A1 (es) | 2007-01-10 | 2009-04-22 | Inst Di Reserche D Biolog Mole | Indazoles sustituidos con amida como inhibidores de poli (adp- ribosa) polimerasa (parp) |
| US20100105688A1 (en) | 2007-01-24 | 2010-04-29 | Glaxo Group Limited | Pharmaceutical compositions comprising 3,5-diamino-6-(2,3-dichlophenyl)-1,2,4-triazine or r(-)-2,4-diamino-5-(2,3-dichlorophenyl)-6-fluoromethyl pyrimidine and an nk1 |
| US8106086B2 (en) | 2007-04-02 | 2012-01-31 | Msd K.K. | Indoledione derivative |
| AU2008269154B2 (en) | 2007-06-27 | 2014-06-12 | Merck Sharp & Dohme Llc | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| CN102014631A (zh) | 2008-03-03 | 2011-04-13 | 泰格尔医药科技公司 | 酪氨酸激酶抑制剂 |
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| US8691825B2 (en) | 2009-04-01 | 2014-04-08 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
| EP2429296B1 (de) | 2009-05-12 | 2017-12-27 | Albany Molecular Research, Inc. | 7-([1,2,4,]triazol[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorphenyl)-1,2,3,4- tetrahydroisochinolin und seine verwendung |
| CN102638982B (zh) | 2009-05-12 | 2015-07-08 | 百时美施贵宝公司 | (S)-7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉的晶型及其用途 |
| MX2011011901A (es) | 2009-05-12 | 2012-01-20 | Albany Molecular Res Inc | Tetrahidroisoquinolinas aril, heteroaril, y heterociclo sustituidas y uso de las mismas. |
| AU2010307198B9 (en) | 2009-10-14 | 2014-02-13 | Merck Sharp & Dohme Corp. | Substituted piperidines that increase p53 activity and the uses thereof |
| EP2584903B1 (de) | 2010-06-24 | 2018-10-24 | Merck Sharp & Dohme Corp. | Neue heterozyklische verbindungen als erk-hemmer |
| JP6043285B2 (ja) | 2010-08-02 | 2016-12-14 | サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 低分子干渉核酸（ｓｉＮＡ）を用いたカテニン（カドヘリン結合型タンパク質）β１（ＣＴＮＮＢ１）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| LT2606134T (lt) | 2010-08-17 | 2019-07-25 | Sirna Therapeutics, Inc. | Hepatito b viruso (hbv) geno raiškos slopinimas, tarpininkaujant rnr interferencijai naudojant mažą interferuojančią nukleorūgštį (sina) |
| EP2608669B1 (de) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | Neue pyrazolo-[1,5-a-]pyrimidinderivate als mtor-hemmer |
| US8946216B2 (en) | 2010-09-01 | 2015-02-03 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
| EP2615916B1 (de) | 2010-09-16 | 2017-01-04 | Merck Sharp & Dohme Corp. | Kondensierte pyrazolderivate als neue erk-hemmer |
| WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
| EP2654748B1 (de) | 2010-12-21 | 2016-07-27 | Merck Sharp & Dohme Corp. | Indazolderivate als erk-hemmer |
| EP2699568A1 (de) | 2011-04-21 | 2014-02-26 | Piramal Enterprises Limited | Kristalline form eines morpholinsulfonylindolderivat-salzes und verfahren zu seiner herstellung |
| EP2770987B1 (de) | 2011-10-27 | 2018-04-04 | Merck Sharp & Dohme Corp. | Neue verbindungen als erk-hemmer |
| EP3453762B1 (de) | 2012-05-02 | 2021-04-21 | Sirna Therapeutics, Inc. | Sina-zusammensetzungen |
| EP2900241B1 (de) | 2012-09-28 | 2018-08-08 | Merck Sharp & Dohme Corp. | Neuartige verbindungen als erk-hemmer |
| AU2013352568B2 (en) | 2012-11-28 | 2019-09-19 | Merck Sharp & Dohme Llc | Compositions and methods for treating cancer |
| ES2707305T3 (es) | 2012-12-20 | 2019-04-03 | Merck Sharp & Dohme | Imidazopiridinas sustituidas como inhibidores de HDM2 |
| US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
| EP3041938A1 (de) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Kreisförmige polynukleotide |
| WO2018071283A1 (en) | 2016-10-12 | 2018-04-19 | Merck Sharp & Dohme Corp. | Kdm5 inhibitors |
| US11098059B2 (en) | 2017-11-08 | 2021-08-24 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| WO2019094311A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| WO2020033284A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| US11993602B2 (en) | 2018-08-07 | 2024-05-28 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| US12173026B2 (en) | 2018-08-07 | 2024-12-24 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| US20220288028A1 (en) * | 2019-05-30 | 2022-09-15 | The Schepens Eye Research Institute, Inc. | A therapeutic approach for treating non-infectious ocular immunoinflammatory disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5346907A (en) * | 1988-04-05 | 1994-09-13 | Abbott Laboratories | Amino acid analog CCK antagonists |
| JPH03503650A (ja) * | 1988-04-05 | 1991-08-15 | アボツト・ラボラトリーズ | Ｃｃｋアンタゴニストとしてのトリプトファン誘導体 |
| ATE133657T1 (de) * | 1991-07-05 | 1996-02-15 | Merck Sharp & Dohme | Aromatische verbindungen, diese enthaltende pharmazeutische zusammensetzungen und ihre therapeutische anwendung |
| WO1993001169A2 (en) * | 1991-07-05 | 1993-01-21 | Merck Sharp & Dohme Limited | Aromatic compounds, pharmaceutical compositions containing them and their use in therapy |
| WO1993001165A2 (en) * | 1991-07-10 | 1993-01-21 | Merck Sharp & Dohme Limited | Aromatic compounds, compositions containing them and their use in therapy |
| ATE197793T1 (de) * | 1992-08-13 | 2000-12-15 | Warner Lambert Co | Tachykinin antagonistes |
-
1995
- 1995-05-18 JP JP8500947A patent/JPH10501228A/ja not_active Ceased
- 1995-05-18 DE DE69523154T patent/DE69523154T2/de not_active Expired - Fee Related
- 1995-05-18 DK DK95920525T patent/DK0764163T3/da active
- 1995-05-18 NZ NZ287284A patent/NZ287284A/xx unknown
- 1995-05-18 AT AT95920525T patent/ATE206710T1/de not_active IP Right Cessation
- 1995-05-18 EE EE9600177A patent/EE03445B1/xx not_active IP Right Cessation
- 1995-05-18 AU AU25950/95A patent/AU693898B2/en not_active Ceased
- 1995-05-18 EP EP95920525A patent/EP0764163B1/de not_active Expired - Lifetime
- 1995-05-18 ES ES95920525T patent/ES2165915T3/es not_active Expired - Lifetime
- 1995-05-18 CA CA002187531A patent/CA2187531A1/en not_active Abandoned
- 1995-05-18 PT PT95920525T patent/PT764163E/pt unknown
- 1995-05-18 WO PCT/US1995/006289 patent/WO1995033744A1/en not_active Ceased
- 1995-06-05 ZA ZA954609A patent/ZA954609B/xx unknown
- 1995-09-07 US US08/525,228 patent/US5610176A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE69523154D1 (de) | 2001-11-15 |
| US5610176A (en) | 1997-03-11 |
| CA2187531A1 (en) | 1995-12-14 |
| WO1995033744A1 (en) | 1995-12-14 |
| EP0764163B1 (de) | 2001-10-10 |
| ATE206710T1 (de) | 2001-10-15 |
| PT764163E (pt) | 2002-03-28 |
| DK0764163T3 (da) | 2002-02-04 |
| EP0764163A1 (de) | 1997-03-26 |
| ZA954609B (en) | 1996-01-26 |
| ES2165915T3 (es) | 2002-04-01 |
| AU2595095A (en) | 1996-01-04 |
| NZ287284A (en) | 1998-10-28 |
| EE9600177A (et) | 1997-06-16 |
| JPH10501228A (ja) | 1998-02-03 |
| DE69523154T2 (de) | 2002-06-06 |
| AU693898B2 (en) | 1998-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69523154D1 (de) | Tachykinin (nk1) rezeptor antagonisten | |
| DE69329712D1 (de) | Tachykinin antagonistes | |
| ES2119174T3 (es) | Azaciclos espiro-sustituidos como antagonistas de los receptores de las taquiquininas. | |
| MY131442A (en) | Excitatory amino acid receptor antagonists | |
| HU9602169D0 (en) | Use of anti-tnf antibodies as drugs in treating diseases involving elevated interleukin-6 serum levels | |
| DE69416869D1 (de) | Diazabicyclische neurokinin antagonisten | |
| KR100521829B1 (en) | Compositions and Methods for the Treatment of Alzheimer's Disease, Central Nervous System Injury, and Inflammatory Diseases | |
| MX9805032A (es) | Analogos de piperidina 4-sustituida y su uso como antagonistas del receptor de d-asparatato de n-metilo, selectivos para el subtipo. | |
| YU56301A (sh) | Inhibitori resorpcije monoamina za tretiranje poremećaja cns | |
| FI935585A0 (fi) | Pyrrolopyrimidiner | |
| ATE297755T1 (de) | Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind | |
| DE69926254D1 (de) | Verwendung von radioliganden zum screening von inhibitoren der herstellung von beta-amyloid peptiden | |
| DE69703617D1 (de) | Verwendung von optisch reines (+) norcisapride zur behandlung von erbrechen und zns-störungen | |
| EA200300807A1 (ru) | Лечение нарушений центральной нервной системы с использованием антагонистов оксидазы d-аминокислот и d-аспартатоксидазы | |
| EA200300040A1 (ru) | 1-аминоалкилциклогексаны в качестве антагонистов 5-нт3 и нейрональных никотиновых рецепторов | |
| EA200300954A1 (ru) | Прегабалин-лактозные конъюгаты | |
| DE69832302D1 (de) | Antikonvulsive und zns-aktive bis-fluoralkylamide | |
| NZ533358A (en) | 3,4-Dihydro-1H-isoquinolin-2-yl-derivatives for use as NK2 receptor antagonists | |
| ATE369354T1 (de) | Isochinolin-aroylpyrrole für die behandlung von krankheiten des zentralnervensystems | |
| HRP20030956A2 (en) | USE OF 1,2-DIAZA-DIBENZO[e,h]AZULENES FOR THE MANU | |
| DE602004008796D1 (de) | VERWENDUNG VON 1,3-DIAZADIBENZOÄe,hÜ AZULENEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN FORMULIERUNGEN FÜR DIE BEHANDLUNG UND PRÄVENTION VON ERKRANKUNGEN UND STÖRUNGEN DES ZENTRALEN NERVENSYSTEMS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB4A | Valid patent at the end of a year |
Effective date: 20021231 |
|
| KB4A | Valid patent at the end of a year |
Effective date: 20031231 |
|
| KB4A | Valid patent at the end of a year |
Effective date: 20041231 |
|
| MM4A | Lapsed by not paying the annual fees |
Effective date: 20050518 |